CHRND

Across TCGA pan-cancer cohorts, CHRND RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated CHRND data layer compared with 7 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CHRND RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CHRND expression acts as an unfavorable survival marker, although some lineages such as UVM and UCS show a favorable association.

LIHC, HNSC, and LGG are the cancer types where CHRND RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.614	0.776	.001	85	view →
HNSC	OS	Median	II,III,IV	0.579	0.724	<.001	64	view →
LGG	DFS	Median	All	0.657	0.818	<.001	54	view →
CESC	DFS	Median	II,III,IV	0.671	0.865	<.001	46	view →
KIRC	OS	Tertile	All	0.765	0.867	.001	45	view →
COAD	OS	Median	All	0.459	0.636	.007	38	view →
SKCM	OS	Median	All	0.789	0.933	.003	35	view →
LUSC	DFS	Quartile	III,IV	0.379	0.755	<.001	25	view →
SCLC	DFS	Tertile	All	0.192	0.793	.017	18	view →
LUAD	DFS	Quartile	IV	0.360	0.851	.017	18	view →
ACC	DFS	Median	All	0.286	0.597	.006	17	view →
UVM	OS	Tertile	II,III,IV	0.862	0.523	.005	17	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

CHRND–LIHC (OS)

Open the LIHC breakdown →